HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen B Keysar Selected Research

IPI-926

2/2016A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.
6/2013Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen B Keysar Research Topics

Disease

17Neoplasms (Cancer)
10/2021 - 09/2010
12Squamous Cell Carcinoma of Head and Neck
01/2022 - 06/2013
5Head and Neck Neoplasms (Head and Neck Cancer)
01/2022 - 06/2013
2Neoplasm Metastasis (Metastasis)
10/2013 - 09/2010
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022
1Bites and Stings (Sting)
10/2021
1Melanoma (Melanoma, Malignant)
01/2021
1Lung Neoplasms (Lung Cancer)
01/2017
1Residual Neoplasm
01/2017
1Squamous Cell Neoplasms (Squamous Cell Cancer)
08/2013
1Hypoxia (Hypoxemia)
01/2010

Drug/Important Bio-Agent (IBA)

5Cetuximab (Erbitux)FDA Link
10/2021 - 06/2013
4ErbB Receptors (EGF Receptor)IBA
01/2022 - 06/2013
4Biomarkers (Surrogate Marker)IBA
10/2021 - 03/2014
4Proteins (Proteins, Gene)FDA Link
10/2021 - 01/2018
3Phosphatidylinositols (Phosphatidylinositol)IBA
01/2022 - 10/2013
3Messenger RNA (mRNA)IBA
10/2021 - 01/2015
3Pharmaceutical PreparationsIBA
10/2020 - 08/2013
2Phosphotransferases (Kinase)IBA
01/2017 - 01/2015
2Aldehyde DehydrogenaseIBA
01/2017 - 09/2010
2IPI-926IBA
02/2016 - 06/2013
2Monoclonal AntibodiesIBA
01/2015 - 06/2013
2Polo-Like Kinase 1IBA
03/2014 - 10/2013
2ON 01910IBA
03/2014 - 10/2013
2CateninsIBA
03/2014 - 10/2013
1Conditioned Culture MediaIBA
01/2022
1Fibronectins (Fibronectin)IBA
10/2021
1Caveolin 1IBA
10/2021
1HLA-A Antigens (HLA-A)IBA
01/2021
1HLA Antigens (Human Leukocyte Antigens)IBA
01/2021
1Interferon-gamma (Interferon, gamma)IBA
01/2021
1HomoharringtonineIBA
01/2020
1CytokinesIBA
11/2019
1MAP-kinase-activated kinase 2IBA
11/2019
1Small Interfering RNA (siRNA)IBA
11/2019
1OMP-54F28IBA
01/2019
1LigandsIBA
01/2019
1Antigen-Antibody Complex (Immune Complex)IBA
11/2018
1Tyrosine Kinase InhibitorsIBA
01/2015
1Transforming Growth Factor beta (TGF-beta)IBA
01/2015
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2015
1tyrosine receptor (receptor, tyrosine)IBA
01/2015
1cyclopamineIBA
12/2014
1Cadherins (E-Cadherin)IBA
10/2013
1Antineoplastic Agents (Antineoplastics)IBA
08/2013
1PX-866IBA
08/2013
1Transcription Factors (Transcription Factor)IBA
06/2013
1Coloring Agents (Dyes)IBA
09/2010
1Membrane Proteins (Integral Membrane Proteins)IBA
09/2010
1Dimethyl Sulfoxide (DMSO)FDA LinkGeneric
01/2010

Therapy/Procedure

11Therapeutics
10/2021 - 09/2010
2Radiotherapy
11/2019 - 12/2014
1Immunotherapy
01/2021
1Aftercare (After-Treatment)
02/2016